Key Highlights: Major Indian Pharma Companies – July 2025

Aurobindo Pharma Limited

• Began sales to Europe through its China-based facility starting April 2025.

Biocon Limited

• Announced a planned capital expenditure of USD 150 million over the next two years.
  • USD 100 million allocated for biologics.
  • USD 50 million for the generics business.

Cipla Limited

• Invested approximately ZAR 900 million in Cipla Medpro South Africa Proprietary Limited (wholly owned subsidiary).
  • Aim: reduce inter-group debt and improve capital structure.

Divi’s Laboratories Limited

• Signed a long-term manufacturing and supply agreement for advanced intermediates with a global pharma company.
• Planning capacity expansion with an investment of INR 6,500–7,000 million, funded from internal accruals.

Dr. Reddy’s Laboratories Limited

• Entered an agreement to sell 14 Abbreviated New Drug Applications (ANDAs), with 13 already approved by the US FDA.
• Expanded partnership with Sanofi's Indian division (SHIPL) to introduce Beyfortus (containing monoclonal antibody Nirsevimab) to the Indian market.

Glenmark Pharmaceuticals Limited

• Acquired the ANDA for Acetylcysteine injection from Aspen Pharma USA Inc., broadening its injectables portfolio.

Lupin Limited

• Formed a partnership with Honeywell to develop eco-friendly inhalers using Solstice Air propellant.
• Acquired UK-based Renascience Pharma Limited for about GBP 12.3 million.

Mankind Pharma Limited

• Established new wholly owned subsidiaries in Sri Lanka and Russia to grow its international presence.
• Formed a partnership with Innovent Biologics to exclusively license and market cancer immunotherapy Sintilimab in India.
• Completed the amalgamation of Shree Jee Laboratory, JPR Labs, and Jaspack Industries.
• Planning the integration of Bharat Serums & Vaccines (BSV).

Sun Pharmaceutical Industries Limited

• Signed an agreement to acquire Checkpoint Therapeutics (a Nasdaq-listed firm specializing in immunotherapy and targeted oncology) for USD 355 million (approx. INR 30,995 million).

Torrent Pharmaceuticals Limited

• Acquired three anti-diabetes brands from Boehringer Ingelheim International GmbH.
• Took a majority stake in JB Chemicals for INR 195,000 million.

Zydus Lifesciences Limited

• Acquired an 85.6% stake in French medical devices company Amplitude Surgical for EUR 256.8 million (approx. USD 280 million).
• Marked a significant expansion into the global medical technology sector, moving beyond traditional pharmaceuticals.

Short Summary

The July 2025 industry report demonstrates robust growth and strategic global expansion among India's leading pharmaceutical companies. Notable activities include major capital investments, expansion into international markets, targeted acquisitions in both pharma and medical technology sectors, and partnerships to introduce innovative therapies. Companies such as Aurobindo, Biocon, Cipla, and Dr. Reddy’s are investing heavily in manufacturing and international collaborations, while others like Lupin, Mankind Pharma, Sun Pharma, Torrent, and Zydus enhance their market presence through key acquisitions and specialty focus. Collectively, these initiatives reinforce Indian pharma’s competitive edge both domestically and worldwide